Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Aficamten in non-obstructive hypertropic cardiomyopathy (nHCM). The expected timing is based on the latest available company guidance and may change.
Suspected Big Mover. ACACIA-HCM trial (non-obstructive HCM). Q3 '24- Enrollment ongoing in pivotal Ph3 trial for non-obstructive HCM. 2/27/25- Complete enrollment in H2 2025. 5/6/25- Topline results in H1 2026. 11/05/25:- Completed enrollment in Japan cohort; topline primary cohort (excluding Japan) Phase 3 results expected in Q2 2026. 02/24/26:- ACACIA-HCM Ph3 topline results reiterated for Q2 2026; Japan cohort ongoing. 05/05/26:- ACACIA-HCM Ph3 topline positive; met dual endpoints. Medical meeting presentation and FDA discussions planned. Full ACACIA-HCM results will be presented at a future medical congress. 07/07/26:- ACACIA-HCM Ph3 primary results at ESC Hot Line Aug 28, 2026; additional analyses Aug 29. 08/06/26:- ACACIA-HCM full results expected in August; nHCM sNDA expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.